Approval of Aducanumab for Alzheimer Disease-The FDA's Perspective

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	JAMA internal medicine Jg. 181; H. 10; S. 1276
Hauptverfasser:	Dunn, Billy, Stein, Peter, Cavazzoni, Patrizia
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	United States 01.10.2021
Schlagworte:	Alzheimer Disease - diagnosis Alzheimer Disease - drug therapy Amyloid beta-Peptides - antagonists & inhibitors Antibodies, Monoclonal, Humanized - administration & dosage Antibodies, Monoclonal, Humanized - adverse effects Antibodies, Monoclonal, Humanized - economics Brain - diagnostic imaging Brain - pathology Decision Making Dose-Response Relationship, Drug Drug Approval - methods Humans Infusions, Intravenous - methods Magnetic Resonance Imaging - methods Nootropic Agents - administration & dosage Nootropic Agents - adverse effects Nootropic Agents - economics Plaque, Amyloid - diagnostic imaging Positron-Emission Tomography - methods Product Surveillance, Postmarketing Randomized Controlled Trials as Topic - methods Treatment Outcome United States United States
ISSN:	2168-6114, 2168-6114
Online-Zugang:	Weitere Angaben
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!